LISATA THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LISATA THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $35.28M | Mar 17, 2017 |
| FY2015 | Dec 31, 2015 | $7.6K | Mar 15, 2016 |
| FY2015 | Sep 30, 2015 | $5.9K | Mar 15, 2016 |
| FY2015 | Jun 30, 2015 | $5.9K | Mar 15, 2016 |
| FY2015 | Mar 31, 2015 | $3.2K | Mar 15, 2016 |
| FY2015 | Dec 31, 2014 | $5.3K | Mar 15, 2016 |
| FY2015 | Sep 30, 2014 | $4.1K | Mar 15, 2016 |
| FY2015 | Jun 30, 2014 | $4.5K | Mar 15, 2016 |
| FY2015 | Mar 31, 2014 | $4.1K | Mar 15, 2016 |
| FY2014 | Dec 31, 2013 | $4.1K | Mar 2, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $170.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | $1.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Feb 29, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $1.72M | Mar 13, 2014 |
| FY2012 | Dec 31, 2012 | $2.38M | Mar 11, 2013 |
| FY2012 | Dec 31, 2011 | $1.40M | Mar 11, 2013 |
| FY2011 | Dec 31, 2010 | $20.15M | Mar 20, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | ($16.59M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | ($19.99M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($20.84M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($54.23M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($27.47M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($8.15M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($19.36M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($16.17M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $22.98M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($32.66M) | Mar 22, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | ($18.21M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | ($22.41M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($25.71M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($57.60M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($29.05M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($19.15M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($20.09M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($16.99M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($27.59M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($29.50M) | Mar 22, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $17.68M | Mar 22, 2022 |
| FY2021 | Dec 31, 2020 | $9.25M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $10.80M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $7.59M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $15.84M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $16.70M | Mar 22, 2018 |
| FY2016 | Dec 31, 2015 | $23.90M | Mar 17, 2017 |
| FY2015 | Dec 31, 2014 | $29.19M | Mar 15, 2016 |
| FY2015 | Dec 31, 2013 | $16.92M | Mar 15, 2016 |
| FY2014 | Dec 31, 2012 | $10.45M | Mar 2, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $12.97M | Feb 29, 2024 |
| FY2023 | Dec 31, 2022 | $14.14M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $11.47M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $9.89M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $9.30M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $9.39M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $11.75M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $12.80M | Mar 22, 2018 |
| FY2016 | Dec 31, 2015 | $30.01M | Mar 17, 2017 |
| FY2015 | Dec 31, 2014 | $30.81M | Mar 15, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | ($15.95M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | ($19.36M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($20.03M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($21.17M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($22.25M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($8.82M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($18.88M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($19.99M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($20.88M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($23.67M) | Mar 22, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $28.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | $0 | Mar 12, 2026 |
| FY2023 | Dec 31, 2023 | $0 | Feb 29, 2024 |
| FY2023 | Dec 31, 2022 | $285.0K | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $60.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $20.0K | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $134.0K | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $135.0K | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.10M | Mar 22, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $17.74M | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | $35.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $54.69M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $73.03M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $97.01M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $36.00M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $27.15M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $44.58M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $63.38M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $53.51M | Mar 22, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $3.14M | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | $5.69M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $6.80M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $6.71M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $5.01M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $3.76M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $6.60M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $7.13M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $13.19M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $30.05M | Mar 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $14.86M | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | $29.57M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $48.15M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $66.58M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $92.25M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $32.50M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $20.82M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $37.73M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $50.51M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $4.88M | Mar 22, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $7.01M | Mar 17, 2017 |
| FY2016 | Dec 31, 2015 | $7.01M | Mar 17, 2017 |
| FY2015 | Dec 31, 2014 | $25.21M | Mar 15, 2016 |
| FY2015 | May 8, 2014 | $14.09M | Mar 15, 2016 |
| FY2014 | Dec 31, 2013 | $11.12M | Mar 2, 2015 |
| FY2013 | Dec 31, 2012 | $11.12M | Mar 13, 2014 |
| FY2012 | Dec 31, 2011 | $11.12M | Mar 11, 2013 |
| FY2012 | Jan 19, 2011 | $7.01M | Mar 11, 2013 |
| FY2011 | Dec 31, 2010 | $27.00M | Mar 20, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | ($564.65M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | ($548.07M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($528.08M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($507.24M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($453.02M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($425.55M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($417.40M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($397.98M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($381.81M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($404.79M) | Mar 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $15.96M | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | $16.21M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $22.59M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $32.15M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $24.65M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $16.51M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $14.03M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $10.30M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $29.16M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $7.08M | Mar 22, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $0 | Mar 2, 2015 |
| FY2014 | Dec 31, 2013 | $3.02M | Mar 2, 2015 |
| FY2013 | Dec 31, 2012 | $0 | Mar 13, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | (1) | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | (2) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | (7) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 22, 2022 |
| FY2018 | Dec 31, 2018 | (1) | Mar 14, 2019 |
| FY2018 | Dec 31, 2017 | 2 | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | (4) | Mar 22, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | (1) | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | (2) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | (7) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 22, 2022 |
| FY2017 | Dec 31, 2017 | 2 | Mar 22, 2018 |
| FY2017 | Dec 31, 2016 | (4) | Mar 22, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | 8.83M | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | 8.41M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 8.15M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 7.87M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 3.99M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 19.38M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | 10.52M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 9.87M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | 9.48M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 8.21M | Mar 22, 2018 |